Business
Curaleaf International Advances Accessibility of Medical Cannabis Products in Germany with Strategic Partnership
Curaleaf International Advances Accessibility of Medical Cannabis Products in Germany wit...
About this update from Curaleaf Holdings, Inc.
[{"type":"text","content":"\n \n \n \n Curaleaf International Advances Accessibility of Medical Cannabis Products in Germany with Strategic Partnership\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP-COLOR:; VERTICAL-ALIGN: BOTTOM; BORDER-LEFT-COLOR:; BORDER-BOTTOM-COLOR:; TEXT-ALIGN: RIGHT; PADDING-LEFT:0.50em; BORDER-RIGHT-COLOR:; PADDING-RIGHT:0.50em\n}\n.prngen1{\nBORDER-TOP-COLOR:; VERTICAL-ALIGN: BOTTOM; BORDER-LEFT-COLOR:; BORDER-BOTTOM-COLOR:; PADDING-LEFT:0.50em; BORDER-RIGHT-COLOR:; PADDING-RIGHT:0.50em\n}\n \n \n \n \n \n \n Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Focus on Treatments for Neurological Therapies\n \n \n Canada NewsWire\n \n \n \n \n \n LONDON\n \n ,\n \n June 29, 2021\n \n /CNW/ -- Curaleaf International (formerly EMMAC Life Sciences Group),\n \n Europe's\n \n largest vertically integrated cannabis company, is pleased to announce that its wholly owned subsidiary, Adven GmbH (\"Adven\"), has announced a strategic partnership with Zambon GmbH, the German subsidiary of Zambon Spa, an Italian multinational pharmaceutical company, leading in Parkinson's Disease, severe respiratory diseases and pain. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. The first treatment will launch in\n \n Germany\n \n in Summer 2021.\n \n \n \"We are delighted to be announcing this partnership with Zambon today, and to be working with a leading pharmaceutical company to create the first European pharmaceutical and medical cannabis partnership; we believe it is testament to our continued commitment to research-led product excellence at Curaleaf International,\" says Curaleaf International CEO,\n \n Antonio Costanzo\n \n . \"We are looking forward to strengthening our collaboration and the creation of more such partnerships, where relevant pharmaceutical and medical cannabis expertise and excellence can be combined to advance the industry's understanding of medical cannabis for the rapidly growing European patient community.\"\n \n \n \"Supporting...